APA (7th ed.) Citation

Dörner, T., Tanaka, Y., Petri, M. A., Smolen, J. S., Wallace, D. J., Dow, E. R., . . . Hoffman, R. W. (2020). Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Science & Medicine, 7(1), e000424. https://doi.org/10.1136/lupus-2020-000424

Chicago Style (17th ed.) Citation

Dörner, Thomas, et al. "Baricitinib-associated Changes in Global Gene Expression During a 24-week Phase II Clinical Systemic Lupus Erythematosus Trial Implicates a Mechanism of Action Through Multiple Immune-related Pathways." Lupus Science & Medicine 7, no. 1 (2020): e000424. https://doi.org/10.1136/lupus-2020-000424.

MLA (9th ed.) Citation

Dörner, Thomas, et al. "Baricitinib-associated Changes in Global Gene Expression During a 24-week Phase II Clinical Systemic Lupus Erythematosus Trial Implicates a Mechanism of Action Through Multiple Immune-related Pathways." Lupus Science & Medicine, vol. 7, no. 1, 2020, p. e000424, https://doi.org/10.1136/lupus-2020-000424.